Business
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
SHANGHAI & CAMBRIDGE, Mass., March 17, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/2a20ef933266b0edd96aa87598a9ce21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NGCseoztMy1HTiTRv5IVdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2a20ef933266b0edd96aa87598a9ce21","width":480,"height":224}},"lazy":false},{"type":"text","content":"- Zoci data show intracranial response in small-cell lung cancer (SCLC) with brain metastases, as well as activity in other neuroendocrine carcinomas- ZL-6201 will be highlighted in a poster presentation showcasing its potential as an innovative ADC for the treatment of sarcoma and other LRRC15-positive solid tumors- ZL-1222, a PD-1/IL-12, will also be featured in a poster presentation highlighting its potential as a next-generation immunocytokine therapy for the treatment of solid tumors","length":495,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., March 17, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC) for small cell lung cancer (SCLC); ZL-6201, a leucine-rich repeat-containing protein 15 (LRRC15) ADC for the treatment of sarcoma and epithelial tumors with LRRC15 expressing cancer-associated fibroblasts (CAFs); and, ZL-1222, a PD-1 and interleukin-12 (IL-12) signaling attenuated mutein agonist immunocytokine for cancer immunotherapy.","length":860,"tagName":"p"},{"type":"text","content":""The breadth and profile of our global oncology pipeline, highlighted by zoci, ZL-6201, and ZL-1222, underscore our commitment to developing innovative therapies for cancers that remain difficult to treat with current standards of care," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "Leveraging our integrated U.S.-China deve...